Travere Therapeutics Inc [TVTX] stock is trading at $21.2, down -2.03%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TVTX shares have gain 21.14% over the last week, with a monthly amount glided 25.37%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citigroup reaffirmed its Buy rating on June 11, 2025, and dropped its price target to $32. On January 10, 2025, Cantor Fitzgerald initiated with a Overweight rating. Wells Fargo upgraded its rating to a Overweight and increased its price target to $27 on October 21, 2024. Scotiabank initiated its recommendation with a Sector Outperform. Guggenheim upgraded its rating to Buy for this stock on September 09, 2024, but kept the price target unchanged to $25. In a note dated March 27, 2024, Guggenheim downgraded an Neutral rating on this stock.
Travere Therapeutics Inc [TVTX] stock has fluctuated between $10.64 and $25.29 over the past year. Currently, Wall Street analysts expect the stock to reach $21.75 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $21.2 at the most recent close of the market. An investor can expect a potential return of 2.59% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
Travere Therapeutics Inc [NASDAQ:TVTX] reported sales of 333.87M for the trailing twelve months, which represents a growth of 111.49%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.51%, Pretax Profit Margin comes in at -0.51%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -7.18 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 12.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.81 points at the first support level, and at 20.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.69, and for the 2nd resistance point, it is at 22.18.
Ratios To Look Out For
For context, Travere Therapeutics Inc’s Current Ratio is 2.00. Also, the Quick Ratio is 1.98, while the Cash Ratio stands at 0.4. Considering the valuation of this stock, the price to sales ratio is 5.66, the price to book ratio is 57.68.
Transactions by insiders
Recent insider trading involved Cline Christopher R., CHIEF FINANCIAL OFFICER, that happened on Sep 03 ’25 when 454.0 shares were sold. CHIEF FINANCIAL OFFICER, Cline Christopher R. completed a deal on Sep 04 ’25 to sell 119.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER Cline Christopher R. sold 470.0 shares on Aug 27 ’25.
